We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
-20.02%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$1.95B
AUM Growth
-$629M
Cap. Flow
+$98.6M
Cap. Flow %
5.07%
Top 10 Hldgs %
47.94%
Holding
79
New
8
Increased
5
Reduced
2
Closed
5

Top Buys

Rank Stock Value
1
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$67.8M
2
APLS
Apellis Pharmaceuticals
APLS
+$57.6M
3
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$49.7M
4
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$36.8M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$26.1M

Top Sells

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$139M
2
ITOS
iTeos Therapeutics
ITOS
+$41.9M
3
JYAC
Jiya Acquisition Corp. Class A Common Stock
JYAC
+$4.88M
4
RACB
Research Alliance Corp. II Class A Common Stock
RACB
+$4.88M
5
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$3.96M

Sector Composition

Rank Sector Weight
1 Healthcare 96.15%
2 Miscellaneous 3.25%
3 Financials 0.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRTX
1
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$164M 8.45%
2,000,000
– –
SWTX
2
DELISTED
SpringWorks Therapeutics
SWTX
$117M 6.02%
2,075,905
– –
ITOS
3
DELISTED
iTeos Therapeutics
ITOS
$103M 5.28%
3,192,058
-1,152,958
-27% -$41.9M
ONC
4
BeOne Medicines Ltd
ONC
$41B
$94.3M 4.85%
500,000
– –
RVMD icon
5
Revolution Medicines
RVMD
$45.2B
$88.9M 4.57%
3,484,264
– –
RLAY icon
6
Relay Therapeutics
RLAY
$4.17B
$79.9M 4.11%
2,669,132
– –
CYTK icon
7
Cytokinetics
CYTK
$10.3B
$77.3M 3.97%
2,100,000
– –
PMVP icon
8
PMV Pharmaceuticals
PMVP
$66.3M
$72.8M 3.74%
3,498,636
+660,400
+23% +$11.6M
TYRA icon
9
Tyra Biosciences
TYRA
$1.48B
$69M 3.55%
6,448,359
– –
APLS
10
DELISTED
Apellis Pharmaceuticals
APLS
$66.2M 3.4%
+1,303,700
New +$57.6M
RXDX
11
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$64.7M 3.33%
+1,714,000
New +$67.8M
XBI icon
12
State Street SPDR S&P Biotech ETF
XBI
$11.7B
$62.9M 3.23%
700,000
-1,500,000
-68% -$139M
TNGX icon
13
Tango Therapeutics
TNGX
$3.84B
$52.1M 2.68%
6,871,642
– –
MRUS
14
DELISTED
Merus
MRUS
$50.2M 2.58%
1,900,000
– –
RCUS icon
15
Arcus Biosciences
RCUS
$3.84B
$45.2M 2.32%
1,432,200
– –
RETA
16
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$40.6M 2.09%
+1,239,000
New +$36.8M
SAGE
17
DELISTED
Sage Therapeutics
SAGE
$36.2M 1.86%
1,094,000
– –
BPMC
18
DELISTED
Blueprint Medicines
BPMC
$32.4M 1.67%
507,374
– –
IOVA icon
19
Iovance Biotherapeutics
IOVA
$3.94B
$32.2M 1.66%
1,935,133
+835,133
+76% +$12.9M
ANAB icon
20
AnaptysBio
ANAB
$1.7B
$32.2M 1.65%
1,300,000
– –
ACAD icon
21
Acadia Pharmaceuticals
ACAD
$4.8B
$30.6M 1.57%
1,263,930
+1,078,930
+583% +$26.1M
AMLX icon
22
Amylyx Pharmaceuticals
AMLX
$3.78B
$28.3M 1.45%
+2,200,000
New +$49.7M
IDYA icon
23
IDEAYA Biosciences
IDYA
$3.86B
$24.6M 1.27%
2,202,812
– –
RCKT icon
24
Rocket Pharmaceuticals
RCKT
$416M
$23.3M 1.2%
1,466,051
– –
NUVB icon
25
Nuvation Bio
NUVB
$2.38B
$22.8M 1.17%
4,341,009
– –
1
2 3 4

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q1 2022 Portfolio in Review

As of Q1 2022, Boxer Capital held 79 positions worth $1.95B, down 24% from $2.57B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Boxer Capital deployed $98.6M of net new capital in Q1 2022, opening 8 new positions and adding to 5 existing holdings. Its largest new stake was Prometheus Biosciences, Inc. Common Stock: 1,714,000 shares worth $64.7M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 87% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was State Street SPDR S&P Biotech ETF, an estimated $139M trimmed.

  • Boxer Capital's largest Q1 2022 buy was Prometheus Biosciences, Inc. Common Stock: 1,714,000 shares worth $64.7M.
  • Boxer Capital added most to Acadia Pharmaceuticals in Q1 2022, an estimated $26.1M increase.
  • Boxer Capital's biggest Q1 2022 reduction was State Street SPDR S&P Biotech ETF, cutting an estimated $139M.
  • Boxer Capital fully exited Research Alliance Corp. II Class A Common Stock in Q1 2022, selling an estimated $4.88M.
  • Boxer Capital's ten largest holdings make up 48% of its $1.95B portfolio in Q1 2022.
  • Boxer Capital opened 8 new positions and closed 5 in Q1 2022.
  • Boxer Capital's portfolio value fell 24% quarter-over-quarter to $1.95B.

Based on Boxer Capital's 13F filing for Q1 2022, filed 16 May 2022.